脓毒症中的代谢炎症复合体:脓毒症恶病质作为新的潜在治疗靶点
尽管经过数十年专注研究,脓毒症仍是危重症患者的主要死亡原因。重症监护的进步使更多患者度过脓毒症急性期,但越来越多患者进展为慢性危重症。既往抗炎药物随机临床试验未能显示脓毒症患者的生存获益,提示单纯抗炎策略无效,因为抗炎药物会抑制对病原体的免疫反应。与全身炎症反应相关的代谢改变(包括线粒体功能障碍和代谢转换)通过信号通路和信号分子网络紧密相连;防止这些代谢紊乱可能是控制过度炎症的替代途径。对脓毒症及脓毒症相关慢性危重症分子发病机制的新认识促成了对脓毒症恶病质的识别,这是一种与多器官功能障碍相关的危及生命的代谢炎症复合体。本综述讨论了脓毒症恶病质作为改善脓毒症患者临床结局的新靶疾病状态的可能性。
要点
- 脓毒症仍是危重症患者的主要死亡原因,重症监护进步使更多患者度过急性期,但越来越多患者进展为慢性危重症。
- 既往抗炎药物随机临床试验未能显示脓毒症患者生存获益,提示单纯抗炎策略无效,因抗炎药物抑制了针对病原体的免疫反应。
- 与全身炎症反应相关的代谢改变(包括线粒体功能障碍和代谢转换)通过信号通路和信号分子网络紧密相连。
- 防止这些代谢紊乱可能是控制过度炎症的替代途径,但这一可能性尚未被充分探索。
- 对脓毒症及脓毒症相关慢性危重症分子发病机制的新认识促成了对脓毒症恶病质的识别,这是一种与多器官功能障碍相关的危及生命的代谢炎症复合体。
适用人群与场景
- 脓毒症患者,包括度过急性期后进展为慢性危重症的患者。
研究设计与关键结果
- 本综述讨论脓毒症恶病质作为改善脓毒症患者临床结局的新靶疾病状态的可能性;脓毒症恶病质是一种与多器官功能障碍相关的危及生命的代谢炎症复合体。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,防止与全身炎症反应相关的代谢紊乱可能是控制过度炎症的替代途径,但这一可能性尚未被充分探索。
- 作者认为,脓毒症恶病质有潜力作为改善脓毒症患者临床结局的新靶疾病状态。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Despite several decades of focused investigation, sepsis remains a major cause of mortality in critically ill patients. Advancements in intensive care have enabled more patients to survive the acute phase of sepsis than previously, but a growing number of them progress to chronic critical illness. The failure of previous randomized clinical trials of anti-inflammatory agents to show any pro-survival benefit in septic patients underscores current thought that simple anti-inflammatory strategies are ineffective because the inhibitory effect of anti-inflammatory agents undermines the immune response to pathogens. New strategies with the dual capability of ameliorating inflammation in organs while stimulating antimicrobial activity are eagerly awaited. On the other hand, the metabolic alterations associated with systemic inflammatory response, including mitochondrial dysfunction and metabolic shift, are closely linked through a nexus of signaling pathways and signaling molecules. Preventing these metabolic derangements may be an alternative way to control excessive inflammation, an intriguing possibility that has not been fully explored. New insight into the molecular pathogenesis of sepsis and sepsis-associated chronic critical illness has led to the recognition of septic cachexia, a life-threatening form of metabolic inflammatory complex associated with multiple organ dysfunction. The potential for septic cachexia to serve as a novel target disease state to improve the clinical outcome of septic patients is discussed in this review.
参考来源
- Kaneki M. Metabolic Inflammatory Complex in Sepsis: Septic Cachexia as a Novel Potential Therapeutic Target. Shock. 2017. PMID: 28520694. doi:10.1097/SHK.0000000000000906
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。